Prognostic Value of Lymph Node Ratio in Cutaneous Melanoma: A Systematic Review.

age group cutaneous lymph node ratio melanoma metastatic disease overall survival prognosis

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Oct 2021
Historique:
accepted: 29 10 2021
entrez: 6 12 2021
pubmed: 7 12 2021
medline: 7 12 2021
Statut: epublish

Résumé

The prognosis of cutaneous melanoma (CM) is based on the histological characteristics of the primary tumor, such as Breslow depth, ulceration, and mitotic rate. The lymph node ratio (LNR) is the ratio of the involved lymph nodes (LNs) divided by the total number of LNs removed during regional LN dissection. LNR is a prognostic factor for many solid tumors; however, controversies exist regarding CM. This study sought to analyze the role of LNR as a prognostic factor in CM. An extensive literature search was conducted using PubMed, Google Scholar, Medline, and the Cochrane Central Registry of Controlled Trials from January 1966 to July 2015. The keywords included in the search were CM and inclusion of the ratio of positive to the total number of LNs as a prognostic factor. The outcomes analyzed included the number of patients with positive LNs, type of survival analysis, and results from the multivariate analysis. A total of 11 studies involving 12,011 patients with positive LNs were evaluated. No previous randomized controlled trials, meta-analyses, or systematic reviews were identified in the Cochrane database on the prognostic value of LNR in CM. The primary electronic database search resulted in 333 full-text articles. The LN location examined was the cervical, axillary, and inguinal regions in all studies except for one that examined only the inguinal region. All studies except three studied the prognostic value of the LNR as a categorical variable rather than a continuous variable. LNR was categorized as A (≤0.1), B (0.11-0.25), and C (>0.25). All studies identified LNR as an independent predictor of overall survival (OS), disease-free survival (DFS), or disease-specific survival (DSS). The hazard ratio (HR) and confidence interval (CI) associated with either DFS or OS were available only in a few studies. Moreover, pooled HR for OS was 2.08 (95% CI: 1.48 2.92), for DFS was 1.364 (95% CI: 0.92-2.02), and for DSS was 1.643 (95% CI: 0.89-3.0). The LNR provides superior prognostic stratification among patients with CM. Additional adequately powered prospective studies are needed to further define the role of LNR and be included in the staging system of CM and direct adjuvant therapy.

Identifiants

pubmed: 34868763
doi: 10.7759/cureus.19117
pmc: PMC8627641
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e19117

Informations de copyright

Copyright © 2021, Khan et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Ann Surg Oncol. 2015 Jul;22(7):2127-34
pubmed: 25316489
N Engl J Med. 2006 Sep 28;355(13):1307-17
pubmed: 17005948
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Ann Surg Oncol. 2013 Dec;20(13):4370-7
pubmed: 24046102
Ann Surg Oncol. 2010 Dec;17(12):3330-5
pubmed: 20645010
Mod Pathol. 2018 Jan;31(1):24-38
pubmed: 29148538
Ann Surg Oncol. 2013 Mar;20(3):956-63
pubmed: 23064795
Ann Surg Oncol. 2011 Nov;18(12):3300-8
pubmed: 21537867
Dermatol Ther. 2020 Nov;33(6):e14131
pubmed: 32757248
Nat Rev Clin Oncol. 2011 May 24;8(7):426-33
pubmed: 21606968
Cancer. 2000 Jan 1;88(1):88-94
pubmed: 10618610
Arch Ophthalmol. 2001 May;119(5):670-6
pubmed: 11346394
Cancer. 2009 Jun 1;115(11):2384-7
pubmed: 19306419
Ann Surg Oncol. 2012 Nov;19(12):3913-8
pubmed: 22588472
Ann Surg Oncol. 2008 Jan;15(1):310-5
pubmed: 17987346
Am J Clin Dermatol. 2017 Jun;18(3):303-310
pubmed: 28229402
JAMA Dermatol. 2020 Jan 1;156(1):57-64
pubmed: 31721989
J Am Acad Dermatol. 2011 Nov;65(5):1032-47
pubmed: 21868127
J Surg Oncol. 2012 Jan;105(1):15-20
pubmed: 21815149
Br J Cancer. 2016 Mar 29;114(7):801-8
pubmed: 26924424
JAMA. 2004 Dec 8;292(22):2771-6
pubmed: 15585738
Int J Oncol. 2018 Apr;52(4):1071-1080
pubmed: 29532857
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Cancer. 2009 Jun 1;115(11):2505-13
pubmed: 19309746
Ann Oncol. 2017 Jul 1;28(7):1631-1639
pubmed: 28475671
Surgery. 2011 Jul;150(1):83-90
pubmed: 21683860

Auteurs

Jaffar Khan (J)

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA.

Asad Ullah (A)

Pathology, Medical College of Georgia - Augusta University, Augusta, USA.

Nathaniel Matolo (N)

Surgical Oncology, San Joaquin General Hospital, French Camp, USA.

Abdul Waheed (A)

Surgery, San Joaquin General Hospital, French Camp, USA.

Noor Nama (N)

Obstetrics and Gynaecology, Bolan Medical College Complex Hospital Quetta, Quetta, PAK.

Nitasha Sharma (N)

Surgery, San Joaquin General Hospital, French Camp, USA.

Kalyani Ballur (K)

Pathology and Laboratory Medicine, Medical College of Georgia - Augusta University, Augusta, USA.

Lauren Gilstrap (L)

Pathology, Medical College of Georgia - Augusta University, Augusta, USA.

Sohni G Singh (SG)

Surgery, San Joaquin General Hospital, French Camp, USA.

Intisar Ghleilib (I)

Pathology and Laboratory Medicine, Medical College of Georgia - Augusta University, Augusta, USA.

Joseph White (J)

Pathology, Medical College of Georgia - Augusta University, Augusta, USA.

Frederick D Cason (FD)

Surgery, San Joaquin General Hospital, French Camp, USA.

Classifications MeSH